In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American ...

The treatment of mycobacterioses is also complex and limited by the need for multidrug and long-term regimens, often not well tolerated. Optimal dosing of recognized anti-mycobacterial drugs is ...

The following is a summary of “Demographic and clinical features of nontuberculous mycobacteria infection resulting from cosmetic procedures: a systematic review,” published in the December 2024 issue ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the BoardInterim Changes to ...

Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx"，688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug ...

Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025DANBURY, Conn. and WESTLAKE VILLAGE, ...

Pre-Market: 8:00:01 a.m. EST ...

1925.T Daiwa House Industry Co., Ltd.

Through their flaws, resilience, and humanity, these characters resonate deeply, reminding readers of shared experiences and ...

ALX-1 is under clinical development by Vast Therapeutics and currently in Phase I for Bronchiectasis. According to GlobalData, Phase I drugs for Bronchiectasis have a 64% phase transition success rate ...